Clinical Trial Update: CD40L Antagonism in Rheumatoid Arthritis (RA) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a CD40L antagonist for rheumatoid arthritis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CD40L antagonist (CD40 ligand antagonist)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED